Humacyte’s (HUMA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note published on Friday,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock.

HUMA has been the subject of a number of other research reports. Wall Street Zen downgraded Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. Benchmark lowered their price target on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of Humacyte in a report on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Finally, BTIG Research decreased their price objective on shares of Humacyte from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Friday. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.71.

Humacyte Stock Performance

NASDAQ HUMA opened at $0.68 on Friday. The stock has a market capitalization of $126.52 million, a price-to-earnings ratio of -3.38 and a beta of 1.89. The business’s 50 day moving average is $1.04 and its two-hundred day moving average is $1.28. Humacyte has a 12-month low of $0.67 and a 12-month high of $2.93. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Friday, March 27th. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). Humacyte had a negative return on equity of 808.20% and a negative net margin of 1,998.87%.The business had revenue of $0.47 million during the quarter, compared to analysts’ expectations of $1.35 million. Research analysts expect that Humacyte will post -1.27 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Humacyte by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 7,520,055 shares of the company’s stock worth $13,085,000 after buying an additional 520,431 shares in the last quarter. Geode Capital Management LLC increased its holdings in Humacyte by 20.2% during the 4th quarter. Geode Capital Management LLC now owns 3,720,436 shares of the company’s stock valued at $3,574,000 after acquiring an additional 624,220 shares in the last quarter. UBS Group AG increased its holdings in Humacyte by 48.8% during the 4th quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock valued at $2,862,000 after acquiring an additional 976,275 shares in the last quarter. State Street Corp raised its position in Humacyte by 17.8% during the fourth quarter. State Street Corp now owns 2,837,276 shares of the company’s stock worth $2,725,000 after acquiring an additional 429,233 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Humacyte by 5,308.2% in the second quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock valued at $5,516,000 after purchasing an additional 2,590,394 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

More Humacyte News

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and set an outsized $25.00 price target, signaling strong upside expectations from that firm. Benzinga
• Positive Sentiment: Humacyte named Rick McElheny SVP of Business Development to expand collaborations and commercialization efforts—management hire aimed at accelerating partnerships that could drive future revenue. GlobeNewswire: Appointment
• Neutral Sentiment: Full earnings call transcript is available for investors wanting management commentary and Q&A that could clarify outlook and commercial plans. Earnings Call Transcript
• Negative Sentiment: Q4 results: GAAP loss of ($0.13) per share met consensus, but revenue came in at roughly $0.47–0.5M versus analyst expectations near $1.35M (and full‑year sales only $2.0M). The revenue shortfall and low near-term sales reduce near-term visibility and likely pressured the stock. MarketBeat: Earnings Press Release Zacks
• Negative Sentiment: BTIG reduced its price target from $6.00 to $3.00 (still a “buy”), signaling a more cautious near-term outlook from another sell-side firm and lowering consensus upside. Benzinga

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.